



ASX ANNOUNCEMENT

22 May 2026

Vitrafy Life Sciences – USAISR Phase II Results Webinar

Vitrafy Life Sciences Limited (ASX: VFY), (“**Vitrafy**” or “**the Company**”) will host an investor briefing at **9.30am (AEST) on Friday, 22 May 2026** to present the results from Phase II of its in-vitro platelet study with the U.S. Army.

The Company invites investors to join the briefing. To attend, please register via the following link:
https://us06web.zoom.us/webinar/register/WN_0TVnMRZjQ6676vxw6cbrBA

After registering, you will receive a confirmation email containing information on how to join the briefing.

Investors are encouraged to submit any questions in advance to Vitrafy’s Investor Relations using the contact details below.

ENDS

This announcement is authorised by the Company Secretary of Vitrafy Life Sciences Limited.

For further information contact:

Investor and Media Relations

Tim Sharpe

Vice President of Strategy & Corporate Development

investors@vitrafy.com

About Vitrafy Life Sciences Limited

Vitrafy Life Sciences Limited (ASX: VFY) has developed breakthrough cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets (>88% recovery vs >50% industry standard), cell & gene therapies (96% viability vs 70% industry minimum), aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain™ software platform, and Smart Packaging systems.

For more information visit vitrafy.com.